Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device
Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.
13 February 2026
13 February 2026
Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.